N-(4-(4-(2-halogenophenyl)piperazin-1-yl)butyl) substituted cinnamoyl amide derivatives as dopamine D2 and D3 receptor ligands

Archiv der Pharmazie

Volumn 340, Issue 4, 2007, Pages 178-184

  Saur, Oliver ^a   Hackling, Anneke E ^a   Perachon, Sylvie ^b   Schwartz, Jean Charles ^b,c   Sokoloff, Pierre ^c   Stark, Holger ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Laboratoire Bioprojet   (France)

^c CENTRE PAUL BROCA   (France)

Author keywords

Cinnamic acids; D3 receptors; Dopamines; PET; Phenylpiperazines

Indexed keywords

3 (4 AMINOPHENYL) N [4 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]BUTYL]ACRYLAMIDE; 3 (4 CHOROPHENYL) N [4 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]BUTYL]ACRYLAMIDE; AMIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; N [4 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]BUTYL] 3,3 DIPHENYLACRYLAMIDE; N [4 [4 (2 HALOGENOPHENYL)PIPERAZIN 1 YL]BUTYL] 3 PHENYLACRYLAMIDE; UNCLASSIFIED DRUG; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; HALOGENATED HYDROCARBON; LIGAND;

ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MITOGENESIS; PRIORITY JOURNAL; ALKYLATION; ANIMAL; CELL LINE; CHEMISTRY; CHO CELL; CRICETULUS; DRUG EFFECT; HAMSTER; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

ALKYLATION; ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; HYDROCARBONS, HALOGENATED; INDICATORS AND REAGENTS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 34250847652     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200600196     Document Type: Article

References (29)

1. A. A. Carlsson, Science 2001, 293, 1021-1024.
2. L. Thorn, T. E. Ashmeade, V. J. Storey, C. Routledge, C. Reavill, Neuropharmacology 1997, 36, 787-792.
3. M. Pilla, S. Perachon, F. Sautel, F. Garridol, et al., Nature 1999, 400, 371-375.
4. J. C. Schwartz, J. Diaz, C. Pilon, P. Sokoloff, Brain Res. Rev. 2000, 31, 277-287.
5. J. N. Joyce, Pharmacol. Ther. 2001, 90, 231-259.
6. A. H. Newman, P. Grundt, M. A. Nader, J. Med. Chem. 2005, 48, 3663-3679.
7. A. E. Hackling, H. Stark, ChemBioChem. 2002, 3, 946-961.
8. A. Preti, Curr. Opin. Investig. Drugs 2000, 1, 110-115.
9. F. J. Garcia-Ladona, B. F. Cox, CNS Drug Rev. 2003, 9, 141-158.
10. U. R. Mach, A. E. Hackling, S. Perachon, S. Ferry, et al., Chembiochem. 2004, 5, 508-518.
11. B. Weber, E. Schlicker, P. Sokoloff, H. Stark, Br. J. Pharmacol. 2001, 133, 1243-1248.
12. B. Le Foll, P. Sokoloff, H. Stark, S. R. Goldberg, Neuropsychopharmacology 2005, 30, 720-730.
13. E. Bezard, S. Ferry, U. Mach, H. Stark, et al., Nat. Med. 2003, 9, 762-767.
14. A. Hackling, R. Ghosh, S. Perachon, A. Mann, et al., J. Med. Chem. 2003, 46, 3883-3899.
15. L. Bettinetti, K. Schlotter, H. Hübner, P. Gmeiner, J. Med. Chem. 2002, 45, 4594-4597
16. Y.-H. Wu, K. R. Smith, J. W. Rayburn, J. W. Kissel, J. Med. Chem. 1969, 12, 876-881
17. G. Jones, in Organic Reactions, Wiley, New York, 1967, 15, pp. 205-301.
18. M. S. Kharash, S. S. Kane, H. C. Brown, J. Am. Chem. Soc. 1942, 64, 333-334.
19. F. Bergmann, M. Weizmann, E. Dimant, J. Patai, J. Szmuskowicz, J. Am. Chem. Soc. 1948, 70, 1612-1617.
20. R. E. Lyons, L. T. Smith, Chem. Ber. 1927, 60, 173-182.
21. A. Hackling, R. Ghosh, S. Perachon, A. Mann, et al., J. Med. Chem. 2003, 46, 3883-3899.
22. N. E. Austin, K. Y. Avenell, I. Boyfield, C. L. Branch, et al., Bioorg. Med. Chem. Lett. 1999, 9, 179-184.
23. F. Sautel, N. Griffon, D. Lévesque, C. Pilon, et al., Neuroreport 1995, 6, 329-332.
24. H. O. Kalkman, D. Feuerbach, E. Lötscher, P. Schoeffter, Life Sci. 2003, 73, 1151-1159.
25. S. Löber, T. Aboul-Fadl, H. Hübner, P. Gmeiner, Bioorg. Med. Chem. Lett. 2002, 12, 633-636.
26. P. Sokoloff, M. Andrieux, R. Besancon, C. Pilon, et al., Eur. J. Pharmacol. [Mol. Pharmacol. Sec.] 1992, 225, 331-337.
27. D. Levesque, J. Diaz, C. Pilon, M. P. Martres, et al., Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8155-8159.
28. F. Sautel, N. Griffon, P. Sokoloff, J. C. Schwartz, et al., J. Pharmacol. Exp. Ther. 1995, 275, 1239-1246.
29. Y. C. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.